KR20090047470A - 단백질 응집을 예측하고 응집 억제제를 고안하는 방법 - Google Patents

단백질 응집을 예측하고 응집 억제제를 고안하는 방법 Download PDF

Info

Publication number
KR20090047470A
KR20090047470A KR1020097002794A KR20097002794A KR20090047470A KR 20090047470 A KR20090047470 A KR 20090047470A KR 1020097002794 A KR1020097002794 A KR 1020097002794A KR 20097002794 A KR20097002794 A KR 20097002794A KR 20090047470 A KR20090047470 A KR 20090047470A
Authority
KR
South Korea
Prior art keywords
protein
peptide
aggregation
peptide sequence
identified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097002794A
Other languages
English (en)
Korean (ko)
Inventor
카이 욧트 콜호프
해수스 주르도
미켈레 벤드루스콜로
Original Assignee
론자 바이올로직스 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 론자 바이올로직스 피엘씨 filed Critical 론자 바이올로직스 피엘씨
Publication of KR20090047470A publication Critical patent/KR20090047470A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
KR1020097002794A 2006-08-04 2007-07-24 단백질 응집을 예측하고 응집 억제제를 고안하는 방법 Ceased KR20090047470A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82155306P 2006-08-04 2006-08-04
US60/821,553 2006-08-04

Publications (1)

Publication Number Publication Date
KR20090047470A true KR20090047470A (ko) 2009-05-12

Family

ID=38573441

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097002794A Ceased KR20090047470A (ko) 2006-08-04 2007-07-24 단백질 응집을 예측하고 응집 억제제를 고안하는 방법

Country Status (11)

Country Link
US (1) US8290713B2 (https=)
EP (1) EP2047393A1 (https=)
JP (1) JP2009545756A (https=)
KR (1) KR20090047470A (https=)
CN (1) CN101501694B (https=)
AU (1) AU2007280282B2 (https=)
CA (1) CA2657847A1 (https=)
EA (1) EA016884B1 (https=)
IL (1) IL196551A (https=)
SG (1) SG173405A1 (https=)
WO (1) WO2008015384A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
GB2455102A (en) * 2007-11-28 2009-06-03 Cambridge Entpr Ltd Protein Aggregation Prediction Systems
WO2009128948A1 (en) 2008-04-17 2009-10-22 Peptimmune, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
CN107677828A (zh) * 2008-10-31 2018-02-09 耶鲁大学 子痫前期检测和治疗的方法和组合物
AU2010310895A1 (en) * 2009-10-23 2012-05-03 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using same
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
FI20105629A0 (fi) * 2010-06-03 2010-06-03 Estaja Oy Menetelmä lipidiaktivoituvien entsyymien peptidi-inhibiittoreiden valmistamiseksi ja menetelmällä valmistettuja peptidejä
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
US20120108904A1 (en) * 2010-10-20 2012-05-03 Yong Ma Cleaner for endoscope
CN103772487B (zh) * 2012-10-24 2015-11-25 国家纳米科学中心 一种抑制人胰淀素聚集或毒性的多肽、试剂及其应用
US9618524B2 (en) * 2014-03-26 2017-04-11 Plaxgen Inc. Method, composition, isolation and identification of a plaque particle and related biomarker
CN104502219B (zh) * 2014-12-18 2017-09-29 江苏大学 一种淀粉样多肽聚集抑制剂及其抑制效果评估和验证方法
EP3242955B1 (en) 2015-01-06 2020-05-06 North Carolina State University Modeling ribosome dynamics to optimize heterologous protein production
GB201600176D0 (en) * 2016-01-06 2016-02-17 Cambridge Entpr Ltd Method of identifying novel protein aggregation inhibitors based on chemical kinetics
CA3011719A1 (en) * 2016-01-21 2017-07-27 Protein Dynamic Solutions Llc Method and system for spectral data analysis
US10815271B2 (en) * 2016-06-29 2020-10-27 The Regents Of The University Of California Structure-based peptide inhibitors of alpha-synuclein aggregation
CN106501550A (zh) * 2016-12-09 2017-03-15 江苏大学 基于原子力显微镜氨基酸影响鱼蛋白聚集行为的评价方法
CN111653310B (zh) * 2020-06-29 2023-06-20 北京大学深圳研究生院 含二硫键多肽的结构预测方法及装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781044B2 (en) * 1999-11-05 2005-05-05 Axonyx, Inc. Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof
CA2528627A1 (en) * 2003-06-23 2005-01-06 Neurochem (International) Limited Treatment of protein aggregation disorders
GB0325817D0 (en) 2003-11-05 2003-12-10 Univ Cambridge Tech Method and apparatus for assessing polypeptide aggregation

Also Published As

Publication number Publication date
WO2008015384A1 (en) 2008-02-07
IL196551A0 (en) 2009-11-18
AU2007280282A1 (en) 2008-02-07
EA200970180A1 (ru) 2009-08-28
JP2009545756A (ja) 2009-12-24
SG173405A1 (en) 2011-08-29
AU2007280282B2 (en) 2012-02-02
CA2657847A1 (en) 2008-02-07
CN101501694A (zh) 2009-08-05
US20100160602A1 (en) 2010-06-24
CN101501694B (zh) 2011-11-30
EA016884B1 (ru) 2012-08-30
IL196551A (en) 2013-01-31
US8290713B2 (en) 2012-10-16
WO2008015384A8 (en) 2008-05-15
HK1131239A1 (en) 2010-01-15
EP2047393A1 (en) 2009-04-15

Similar Documents

Publication Publication Date Title
KR20090047470A (ko) 단백질 응집을 예측하고 응집 억제제를 고안하는 방법
Man et al. Effects of all-atom molecular mechanics force fields on amyloid peptide assembly: the case of aβ16–22 dimer
Zhang et al. DPAM: A domain parser for AlphaFold models
Yoon et al. Detecting hidden sequence propensity for amyloid fibril formation
Fallas et al. Computational design of self-assembling register-specific collagen heterotrimers
Pawlicki et al. AMYPdb: a database dedicated to amyloid precursor proteins
Bordas-Le Floch et al. A combined transcriptome and proteome analysis extends the allergome of house dust mite Dermatophagoides species
Kim et al. A high‐throughput predictive method for sequence‐similar fold switchers
Deutsch et al. Tiered human integrated sequence search databases for shotgun proteomics
Childers et al. Edge strand dissociation and conformational changes in transthyretin under amyloidogenic conditions
Linh et al. Impact of mutations at C-terminus on structures and dynamics of Aβ40 and Aβ42: a molecular simulation study
Russo et al. Design, Optimization, and structural characterization of an apoptosis-inducing factor peptide targeting human cyclophilin a to inhibit apoptosis inducing factor-mediated cell death
Wacholder et al. Detection of human unannotated microproteins by mass spectrometry-based proteomics: a community assessment
Black et al. Evaluating calmodulin–protein interactions by rapid photoactivated cross-linking in live cells metabolically labeled with photo-methionine
Puławski et al. Multiscale modeling of protofilament structures: A case study on insulin amyloid aggregates
US20070244651A1 (en) Structure-Based Analysis For Identification Of Protein Signatures: CUSCORE
Bokor et al. Wide-line NMR melting diagrams, their thermodynamic interpretation, and secondary structure predictions for A30P and E46K α-synuclein
Zaki Protein-protein interaction prediction using homology and inter-domain linker region information
HK1131239B (en) Method for predicting protein aggregation and designing aggregation inhibitors
Pantoja-Uceda et al. The NMR structure and dynamics of the two-domain tick carboxypeptidase inhibitor reveal flexibility in its free form and stiffness upon binding to human carboxypeptidase B
Tan et al. Computational analysis of the alpha− 2 domain of apolipoprotein B− 100, a potential triggering factor in LDL aggregation
Garcia et al. Monomer binding modes of small molecules that modulate the kinetics of hIAPP amyloid formation
Tolani et al. Navigating the labyrinth of drugging the disordered
Truant et al. Revisiting huntingtin activity and localization signals in the context of protein structure
Baydur Machine Learning-Assisted and Fluorescence Protein-based Biosensor Design for Amyloid-Beta Detection

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090211

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120723

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131218

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140224

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131218

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I